Inhibition of parasite invasion by monoclonal antibody against epidermal growth factor-like domain of Plasmodium vivax merozoite surface protein 1 paralog by Han, Jin-Hee et al.
1Scientific RepoRts |          (2019) 9:3906  | https://doi.org/10.1038/s41598-019-40321-2
www.nature.com/scientificreports
Inhibition of parasite invasion 
by monoclonal antibody against 
epidermal growth factor-like 
domain of Plasmodium vivax 
merozoite surface protein 1 paralog
Jin-Hee Han1,2, Yang Cheng1,3, Fauzi Muh1, Md Atique Ahmed1, Jee-Sun Cho4,5, 
Myat Htut Nyunt  6, Hye-Yoon Jeon7, Kwon-Soo Ha  7, Sunghun Na8, Won Sun park9, 
seok-Ho Hong10, Ho-Joon shin11, Bruce Russell  2,4 & eun-taek Han1
the Plasmodium vivax merozoite surface protein 1 paralog (PvMSP1P), which has epidermal growth 
factor (EGF)-like domains, was identified as a novel erythrocyte adhesive molecule. This EGF-like 
domain (PvMSP1P-19) elicited high level of acquired immune response in patients. Antibodies against 
PvMSP1P significantly reduced erythrocyte adhesion activity to its unknown receptor. To determine 
PvMSP1P-19-specific antibody function and B-cell epitopes in vivax patients, five monoclonal 
antibodies (mAbs) and 18-mer peptides were generated. The mAb functions were determined by 
erythrocyte-binding inhibition assay and invasion inhibition assay with P. knowlesi. B-cell epitopes 
of PvMSP1P-19 domains were evaluated by peptide microarray. The pvmsp1p-19 sequences showed 
limited polymorphism in P. vivax worldwide isolates. The 1BH9-A10 showed erythrocyte binding 
inhibitory by interaction with the N-terminus of PvMSP1P-19, while this mAb failed to recognize 
PkMSP1P-19 suggesting the species-specific for P. vivax. Other mAbs showed cross-reactivity with 
PkMSP1P-19. Among them, the 2AF4-A2 and 2AF4-A6 mAb significantly reduced parasite invasion 
through C-terminal recognition. The linear B-cell epitope in naturally exposed P. vivax patient was 
identified at three linear epitopes. In this study, PvMSP1P-19 N-terminal-specific 1BH9-A10 and 
C-terminal-specific 2AF4 mAbs showed functional activity for epitope recognition suggesting that 
PvMSP1P may be useful for vaccine development strategy for specific single epitope to prevent P. vivax 
invasion.
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Among the five Plasmodium species that cause malaria in humans, P. vivax is the most widely distributed and 
causes infections worldwide outside Sub-Saharan African regions1. A vaccine to protect against P. vivax is espe-
cially needed due to widespread drug resistance in some countries. However, P. vivax blood-stage vaccine devel-
opment has been limited because of a lack of understanding of invasion mechanisms2. Identifying individual 
antigen and/or antibody functions is one alternative approach to vaccine development.
Many merozoite surface antigens have been discovered to be highly immunogenic in patients who are natu-
rally exposed to human invasive malaria parasites3,4. Likewise, P. vivax merozoite surface protein 1 (PvMSP1) is 
currently suggested as one of the most advanced vaccine candidates in the vivax parasite blood stage5,6. The mero-
zoite surface antigens come up as a critical role at initial contact by complex form of merozoite surface antigen 
with host cells and immune evasion during merozoite internalization by shedding of the surface coat7,8. Updating 
knowledge figures out PfMSP1 processing and functions are important for parasite egress from red blood cells9. 
Although merozoite surface antigens showed immune evasion activity, it could be easier to target by the host anti-
body than apical organelle antigens because it is easily exposed to the host immune system10,11. In contrast, apical 
organelles are only exposed to the immune system for short periods compared to surface molecules due to the 
rapid invasion process. Hence, various merozoite antigens have been proposed as a potential vaccine candidate, 
not only MSP1 but also other surface antigens5. In particular, glycosylphosphatidylinositol (GPI)-anchored mero-
zoite surface antigens, including MSP2, MSP4, MSP5, MSP8, and MSP10, were considered as novel blood-stage 
vaccine candidates5,10,12–14. However, these antigens have a critical disadvantage for vaccine development because 
of high polymorphism. The C-terminal fragments of PvMSP1, PvMSP1P, PvMSP8, and PvMSP10 contain iden-
tical cysteine residues within two of the epidermal growth factor (EGF)-like domains15, which was confirmed by 
conformational crystal structures in various Plasmodium spp.16–18.
Recently, the novel antigen PvMSP1P was reported to localize on the merozoite surface by a GPI-anchored 
motif19. This antigen led to erythrocyte adhesion by two EGF-like domains (PvMSP1P-19) at the C-terminus 
and showed a high level of acquired immune responses in vivax patients19,20. The functional antibody against 
PvMSP1P-19 from a vivax patient demonstrated inhibition activities for erythrocyte adhesion19,20. PvMSP1P 
induced predominant IgG1 and IgG3 antibody responses in vivax-infected patients21,22. These two IgG isotypes 
are highly induced by both of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC) effect. Likewise, antibodies against PfMSP1-19 induced IgG1 and IgG3 and showed mero-
zoite invasion blocking activity by interruption of processing23. The cellular immune response properties in mice 
showed that Th1 cytokine levels were significantly higher than those in PvMSP1-19 immunized mice. Likewise, 
PvMSP1P-19 strongly induced a specific cellular immune response by activation of IFN-γ-producing effector cells 
in natural human infections21. These findings might reflect that PvMSP1P is a feasible vivax vaccine candidate.
A high priority of the invasion blocking vaccine discovery for the blood stage is to identify specific antibody 
functions and immune properties in patients. In the present study, we have demonstrated the functional epitope 
for inhibition of erythrocyte binding and parasite invasion by monoclonal antibodies (mAbs). The result will 
provide an understanding of the protection against P. vivax invasion into erythrocytes and deserve consideration 
for vaccine development.
Results
Primary structure and sequence diversity of PvMSP1P-19. PvMSP1P encoded by 1,854 amino acid 
(aa.) sequence with a 214.5 kDa molecular weight. The primary structure of PvMSP1P has been predicted to 
contain signal peptide (SP, 1 to 28 aa.) at N-terminus, two EGF-like domains (EGF, 1749 to 1834 aa.) and GPI 
anchored domain (GPI, 1834 to 1854 aa.) at C-terminus (Fig. 1a). The central part of ectodomain has hepta-pep-
tide tandem repeat region (TR, 905 to 918 aa.), and Glu/Gln-rich region (PR, 1157 to 1172 aa.) (Fig. 1a).
Sixty-six isolates of pvmsp1p from PlasmoDB (http://plasmodb.org/) originating from 10 countries (Brazil, 
China, Columbia, India, Mauritania, Mexico, North Korea, Peru, Papua New Guinea, and Thailand) were used 
for nucleotide diversity analysis. The nucleotide diversity (π) showed 0.00066 within worldwide isolates, thus 
indicating that pvmsp1p had limited polymorphism (Fig. 1b). The thirty pvmsp1p sequences from Republic of 
Korea (ROK), Thailand and Myanmar were newly sequenced in this study and sequence alignment indicated a 
conserved EGF-like domain (Table 1). The sequence alignfment of thirty isolates are described as Supplementary 
Data 1. The nucleotide diversity (π) comparison between EGF-like domain of pvmsp1-19 (0.00060) and pvm-
sp1p-19 (0.00032) indicated that low polymorphism occurred in pvmsp1p-19 (Supplementary Fig. S1).
Characterization of monoclonal antibodies. To qualify monoclonal antibodies, three hybridoma cells 
were selected for cloning by limiting dilution based on their high absorbance in ELISA. The hybridoma cells 
were named 1BH9, 2AF4, and 3BC6 and showed O.D. values of 1.191, 1.845, and 1.873, respectively (Fig. 2a). In 
total, five mAbs (1BH9-A10: IgG1-κ, 2AF4-A2: IgG3-κ, 2AF4-A6: IgG3-κ, 3BC6-A5: IgG2b-κ and 3BC6-B12: 
IgG2b-κ) were produced, and the IgG isotypes were determined. Immunoblot analysis was performed to deter-
mine whether the five mAbs are responsive to rPvMSP1P-19, which showed an approximately 14 kDa specific 
band (Fig. 2b). The naïve antigen recognition and subcellular localization of mAbs were confirmed by mature 
schizont of P. vivax. All of mAbs were found to be specific to recognize the native parasite antigen, however, 
the strength of recognition was different (Fig. 2c). As a surface antigen control, the PvMSP1-19 polyclonal anti-
body was used to compare the co-localization. Unexpectedly, only 1BH9-A10 clearly overlapped with PvMSP1 
(Fig. 2c). Another four mAbs, 2AF4-A2, 2AF4-A6, 3BC6-A5 and 3BC6-B12, showed diverse scattered recogni-
tion patterns on the merozoite surface (Fig. 2c). Different panels were showed with low magnification in P. vivax 
and P. knowlesi (Supplementary Figs S2 and S3).
Linear epitopes of monoclonal antibodies. To investigate the linear epitopes of monoclonal antibodies, 
eighteen-mer overlapping peptides were synthesized (Fig. 1a) and spotted onto array slide. The spotted peptides 
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were incubated with each monoclonal antibody at 1:200 and measured by goat anti-mouse Alexa Fluor 546 anti-
bodies. 1BH9-A10, 3BC6-A5, and 3BC6-B12 were found to bind at the N-terminal region covering epitope pep-
tides from A1746 to E1773 (Ala1746-Leu1790 in the amino acid position), and strongly recognized at C1755 
(1755CRNRKCPLNSFCFIQTIN1772) (Fig. 3). In contrast, 2AF4-A2 and 2AF4-A6 recognized a single peptide 
C1818 (1818CICPKGTKPMHEGVVCSF1835) at the C-terminal region (Fig. 3).
Erythrocyte binding inhibitory ability. Erythrocyte binding inhibitory ability of PvMSP1P-19 specific 
antibody was confirmed previously19,20. The functional activity of five monoclonal antibodies were confirmed by 
erythrocyte binding inhibition in in vitro system. A serial dilution of each mAb and the non-treated control were 
used for erythrocyte binding inhibition activity confirmation. The inhibitory effects on mAbs were described 
as the percentage of erythrocyte binding inhibition compared to the mock control. 1BH9-A10 showed a bind-
ing inhibitory effect in a concentration-dependent manner (Fig. 4, Supplementary Fig. S4). However, 2AF4-A2, 
2AF4-A6, 3BC6-A5, and 3BC6-B12 did not affect erythrocyte binding inhibition (Fig. 4).
Cross-reactivity with P. knowlesi. P. vivax and P. knowlesi MSP1P EGF domains contained complete con-
servation of cysteine residues with high amino acids sequence similarity (86%)24 (Fig. 5a). Immunoblot analy-
sis was performed with P. knowlesi derived recombinant MSP1P EGF domain and naïve parasite to determine 
cross-reactivity confirmation. Four mAbs clearly recognized the rPkMSP1P-19 and naïve P. knowlesi schizont 
lysate except 1BH9-A10 which has erythrocyte binding inhibition activity (Figs 5b,c). The naïve P. knowlesi 
subcellular recognition by the mAbs in the mature schizont were observed on the merozoite surface. However, 
1BH9-A10 mAb showed poor recognition with P. knowlesi as it is consistent with immunoblotting (Fig. 5d, 
Supplementary Figs S2 and S3). It may suggest the species-specific recognition of 1BH9-A10 mAb to P. vivax.
Figure 1. Schematic structure of PvMSP1P-19 and sequence diversity in worldwide isolate. (a) The schematic 
diagram shown PvMSP1P primary structure. The signal peptide (SP, black box), tandem repeat (TR, orange 
box), polymorphic Glu/Gln-rich region (PR, yellow box), epidermal growth factor like (EGF, Gray box), and the 
glycosylphosphatidylinositol (GPI, blue box) indicates. The 18-mer peptides indicated with amino acid position 
and sequence for peptide microarray. (b) Sliding window plot showing nucleotide diversity (π) values of 
PvMSP1P using 66 worldwide isolates. The grey box represents two EGF-like domains at amino acid positions 
1751 to 1834.
Vivax patients in endemic countries Non-endemic area
Republic of Korea Thailand Myanmar Republic of Korea
Total (n) 11 7 12 30
Age (year)
    Mean ± S.D. 48.50 ± 30.78 36.80 ± 10.99 22.09 ± 7.78 9.20 ± 2.12
    Range 20–89 23–46 14–40 6–13
Parasitaemia (%)
    Mean ± S.D. 0.1813 ± 0.1792 0.1916 ± 0.1089 0.0849 ± 0.0531 —
    Range 0.0100–0.5700 0.07504–0.3049 0.0241–0.1964 —
Table 1. Vivax patient field isolate information. ROK, Republic of Korea; S.D., standard deviation.
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Parasite invasion inhibitory ability. To determine PvMSP1P-19 mAb functions to abrogate merozoite 
invasion, the human erythrocyte-adapted P. knowlesi parasite was used in ex vivo invasion inhibition assay. P. 
knowlesi parasites are used for vivax study model, especially during the blood stage, because of the high sequence 
similarity with conserved cysteine in the EGF-like domain and a feasible in vitro culture24.
The parasites were cultured with or without mAb, and the healthy ring-form morphology of P. knowlesi was 
confirmed under microscopy (Fig. 6a). The healthy morphology of the parasites was reflected by the fact that the 
mAbs did not affect the parasite growth (Fig. 6a). FACS analysis was used for parasitaemia calculations with total 
Figure 2. PvMSP1P-19 monoclonal antibody production and validation. (a) Three clones were successfully 
hybridized to produce monoclonal antibodies, and hybridoma culture supernatants were obtained. The 
OD values were measured by indirect ELISA at 405 nm. Antigen was used at concentrations of 1 µg/ml. 
(b) A western blot showing five monoclonal antibodies reacting with PvMSP1P-19. The approximately 
14 kDa specific band indicates rPvMSP1P-19 (arrow head). His, penta-anti-His antibody; lanes 1–5, anti-
PvMSP1P-19 monoclonal antibodies as follows: lane 1, 1BH9-A10; lane 2, 2AF4-A2; lane 3, 2AF4-A6; lane 4, 
3BC6-A5; and lane 5, 3BC6-B12. (c) Reactivity detection for monoclonal antibodies with native PvMSP1P by 
immunofluorescence assay. The mature schizont of P. vivax was dual labelled with PvMSP1P-19 monoclonal 
antibodies (green) and rabbit immune sera against PvMSP1-19 (red, merozoite surface marker). Nuclei are 
visualized with DAPI (blue). Bar indicate 5 μm.
Figure 3. PvMSP1P-19 monoclonal antibody epitope mapping. The normalized mean fluorescence intensity 
(MFI) was calculated by comparing the no peptide printed slide well MFI value with each peptide printed array 
well MFI value. Data are shown as the mean ± S.D. of four independent experiments.
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cells (total RBCs) followed by single cells (single RBCs) using manual gating strategies. The single RBCs were 
considered feasible forms of P. knowlesi invasion, and the SYBR green range was set to less than log106 to avoid 
the mature stage of parasites or monocyte contamination (Fig. 6b). Invasion inhibition activities of 2AF4-A2 
(23.1 ± 2.0 in mean ± S.D.) and 2AF4-A2 (13.6 ± 3.8) were observed; however, 1BH9-A10 (6.2 ± 2.6), 3BC6-A5 
(6.5 ± 5.1), and 3BC6-A5 (5.1 ± 4.2) did not inhibit parasite invasion significantly compared with pre-immune 
sera (PI, −1.0 ± 0.7) (Fig. 6c). Consistent with previous studies25,26, anti-DARC mAb (2C3, 84.7 ± 1.1) showed 
significant invasion inhibition activity.
PvMSP1P-19 linear B-cell epitope in P. vivax patients. The B-cell linear epitopes of PvMSP1P in nat-
ural infection were identified by peptide array with vivax patient sera (Table 1) at 1:25 dilution and visualized by 
goat anti-human Alexa Fluor 546 antibodies. The normalization of the mean fluorescence intensity (MFI) of the 
average healthy group was compared to that of each peptide group (Table 2, Supplementary Fig. S5). Three pep-
tides, S1764, E1773, and N1791, detected an epitope in the vivax patient that was in line with humoral immune 
reactivity (Table 2). The peptides C1809 (p = 0.0272) and C1818 (p = 0.0012) in the C-terminal region also 
showed significantly high IgG response in patient groups. Among them, E1773 showed the highest sero-positivity 
of 70% (1.80-fold higher than healthy individuals), followed by S1764 and N1791 at 53.3% (1.63-fold) and 50.0% 
(1.62-fold), respectively (Table 2). The C-terminal domain of peptides C1809 and C1818  showed only 20.0% 
(1.19-fold) and 26.7% (1.44-fold) sero-positivity. The first B-cell epitope in the vivax patient was determined to 
be at overlapping sites of S1764 and E1773, which are found in the short peptide 1773EECLCLLNY1781. The second 
linear B-cell epitope was detected at 1791NEQNSCAVKNGGCDLKAT1808. This linear epitope showed that only 
the complete sequence of N1791 can elicit an antibody response, which is at the central part of the sequence of 
the B-cell epitope.
Discussion
According to the P. vivax research in previous reports, merozoite surface antigens such as PvMSP1, PvMSP3α, 
PvMSP3β, PvMSP8, PvMSP9, Pv92, and PvMSA180 elicited high antibodies responses19,27–33. The functional 
activity of antibodies in malaria has multiple roles, such as merozoite invasion inhibition, agglutination, growth 
inhibition, rosetting inhibition, opsonic phagocytosis, and direct killing by complement mediation34. Both P. fal-
ciparum and P. vivax express MSP1, a major antigen of the merozoite surface that is extensively studied. The anti-
body against PfMSP1 EGF-like domain (PfMSP1-19) was confirmed to inhibit invasion in previous reports35,36. 
Processing of MSP1 was also found to play role in parasite viability and merozoite egress9. Additionally, MSP1 
has successfully mapped antibody epitopes and their roles in the two EGF-like domains37. In line with the MSP1 
study, an antibody against the EGF-like domain of PvMSP1P shows functional activity for erythrocyte binding 
Figure 4. Erythrocyte binding inhibitory effect of PvMSP1P-19 monoclonal antibodies. The percentage 
of relative binding was calculated by comparing the number of rosettes between no antibody-treated and 
monoclonal antibody-treated samples. The PvMSP1P-19 specific monoclonal antibody, 1BH9-A10, showed red 
blood cell binding inhibitory activity. Data are shown as the mean ± S.D. of three independent experiments.
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interruption7,20,36,38. Thus, as examined in this study, functional epitopes for immune responses and erythrocyte 
binding ability are important for understanding the biology of P. vivax in patients.
Five monoclonal antibodies were produced and confirmed using indirect fluorescence assay in naïve P. vivax 
and P. knowlesi parasites. The 2AF4-A2, 2AF4-A6, 3BC6-A5, and 3BC6-B12 staining pattern was scattered on 
the vivax merozoite surface. It might be due to that epitope does not expose or masking so that monoclonal 
antibodies could not recognize whole part of PvMSP1P-19 domain as polyclonal antibody does. Meanwhile, 
PvMSP1P-19 in the vivax patients was highly antigenic at the acute phase in 68.0% of ROK (n = 102) and 72.5% 
of Thailand (n = 40) isolates19,39. These antibodies were stable up to nine months after the patient recovered, and 
PvMSP1P-19 in the high responder was directly related to the erythrocyte binding inhibition in in vitro system, 
but not in low responder39. Direct erythrocyte binding inhibition ability showed that 1BH9-A10 mAb recog-
nized the C1755 peptide. However, the C1755 peptide position failed to induce an immune response in most 
vivax patients. This result indicated that the high-responder patient IgG might contain the C1755 recognition 
antibodies. For parasite invasion inhibition, the effective B-cell epitope was identified in the C-terminal domain 
as 1818CICPKGTKPMHEGVVCSF1835. In this position, IgG expression was induced in the patient; however, low 
sero-positivity (26.7%) was observed. Due to the difficulty to perform invasion inhibition assay with P. vivax, 
the invasion inhibition assay was performed with P. knowlesi. P. knowlesi and P. vivax showed high homology 
rate in various antigens including msp1p gene which can be used as an alternative way for vivax study model24,40. 
However, 1BH9-A10 which erythrocyte binding inhibitory mAb did not recognize in P. knowlesi. This result 
Figure 5. Cross-reactivity of PvMSP1P-19 monoclonal antibodies with P. knowlesi. (a) MSP1P EGF-like 
domain (MSP1P-19) amino-acid sequence comparison between PvMSP1 and PkMSP1. The red bar indicates 
identical sequence and blue bar indicates diverse sequence. (b) A western blot showing five monoclonal 
antibodies reacting with recombinant PkMSP1P-19. The approximately 37 kDa specific band indicates 
rPkMSP1P-19 (arrow head). GST, anti-GST antibody; lanes 1–5, anti-PvMSP1P-19 monoclonal antibodies as 
follows: lane 1, 1BH9-A10; lane 2, 2AF4-A2; lane 3, 2AF4-A6; lane 4, 3BC6-A5; and lane 5, 3BC6-B12. (c) A 
western blot showing five monoclonal antibodies reacting with P. knowlesi parasite lysate. The clear multiple 
band indicates processed naïve PkMSP1P-19. Lanes 1–5, anti-PvMSP1P-19 monoclonal antibodies as follows: 
lane 1, 1BH9-A10; lane 2, 2AF4-A2; lane 3, 2AF4-A6; lane 4, 3BC6-A5; and lane 5, 3BC6-B12. P, P. knowlesi 
lysate; R, normal RBC extract. (d) Reactivity observed by PvMSP1P-19 monoclonal antibodies with P. knowlesi 
merozoite at schizont stage by immunofluorescence assay. The mature schizont of P. knowlesi was dual labelled 
with PvMSP1P-19 monoclonal antibodies (green) and rabbit immune sera against PvMSP1-19 (red, merozoite 
surface marker). Nuclei are visualized with DAPI (blue). Bar indicate 5 μm.
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indicated that 1BH9-A10 recognition site was hampered by the polymorphic residues between orthologue at the 
N terminus. Additionally, the discrepancy of erythrocyte binding and invasion inhibition result might be caused 
by following reasons. The invasion inhibitory mAb was also observed in PfMSP1 by inhibition of processing of 
PfMSP1-4236. PvMSP1P also showed processing19, and the mAbs 2AF4-A2 and 2AF4-A6 could inhibit the pro-
cessing of PvMSP1P. Additionally, previous studies indicate that direct binding and antibody recognition sites are 
not related36,41. The parasite growth inhibition ability of mAbs was confirmed by morphological examination. The 
morphology under the mAb treatment condition was maintained in the healthy condition, which indicates that 
mAbs against PvMSP1P-19 have no effect on parasite growth.
The merozoite surface antigen has been identified as a promising vaccine candidate from the malaria asexual 
stage42. Generally, merozoite surface antigens have a major role in invasion as a trigger for initial attachment to 
host target red blood cells10,30,43. Because of surface localization, genetic polymorphisms frequently occur by 
selection from host immune pressure in natural infection44. These polymorphisms are raising a problem in vac-
cine trials45. However, a surface antigen remains a promising target for a malaria vaccine because the merozoite 
surface antigens have a longer exposure time until internalization. To overcome the low efficacy of the malaria 
vaccine, multiple antigen combinations seem to be a good alternative46–48. Along with these combinations, the 
antigen that has resistance to host immune pressure in nature and elicits a high humoral immune response will 
be designed as a single or multiple vaccine candidate. PvMSP1P-19 confirmed that worldwide isolate sequences 
were found limited polymorphism. The conserved sequences will avoid vaccine efficiency problems from allele 
Figure 6. P. knowlesi invasion inhibition activities of PvMSP1P-19 monoclonal antibodies. (a) P. knowlesi 
stages were confirmed by morphology under light microscopy. The black arrow head indicates the mature 
schizont stage of P. knowlesi before invasion. The black arrow points to an unhealthy parasite, and the red 
arrow indicates the healthy ring stage of the parasite after re-invasion. (b) FACS gating strategy of ring stage 
parasitaemia evaluation. The schizont stage parasites are considered to have SYBR green signals of more than 
log 106. (c) The P. knowlesi invasion inhibition efficacy was confirmed by an invasion inhibition assay. Data are 
shown as the invasion inhibition rate mean ± standard deviation (S.D.) with pre-immune sera (PI) and anti-2C3 
(murine anti-Fy6) and PvMSP1P-19 monoclonal antibodies. Significant differences between PI and anti-2C3 or 
monoclonal antibodies calculated with a one-way ANOVA with the Tukey post-test. ***p < 0.001.
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specificity. Taken together, PvMSP1P-19 elicits stable and high IgG responses in vivax patients regardless of 
polymorphisms from host immune pressure. The functions of antibodies showed possibility of parasite inva-
sion abrogation. In summary, two effective epitopes were identified at 1755CRNRKCPLNSFCFIQTIN1772 and 
1818CICPKGTKPMHEGVVCSF1835 for disrupting of PvMSP1P with erythrocytes interaction. However, these 
epitope regions should overcome the lack of natural boosting. Thus, we propose that PvMSP1P can be considered 
for a vaccine design strategy either for multiple or single vaccine development.
Materials and Methods
Sample collection and ethical clearance. The blood samples were collected in three malaria-endemic 
areas of the Republic of Korea (ROK, n = 11), Thailand (n = 7) and Myanmar (n = 12) from 2014 to 2016, 2013 and 
2012, respectively (Table 1). The vivax patient samples were confirmed immediately at the study site by malaria 
antigen using the P.f/Pan rapid diagnosis test kit (SDFK60) (SD Diagnostics, Giheung, Korea) and Giemsa-stained 
thin smears under microscopy. The healthy individual sera were collected from children under 10 years old with 
no malaria history in local hospitals of non-endemic areas, ROK. All experiments were performed in accordance 
with relevant guidelines and regulations and all experimental protocols involving human samples approved by 
the ethics committees of the Kangwon National University Hospital in the ROK (KWNUIRB-2016-04-005), the 
Faculty of Tropical Medicine, Mahidol University in Thailand (MUIRB2012/079.2408), and the Department of 
Medical Research, Republic of the Union of Myanmar (Approval No-52/Ethics, 2012). This study was approved 
by the Institutional Review Board at Kangwon National University Hospital. Written informed consent was 
obtained from all subjects and their guardians.
Genetic diversity analysis. Thirty isolates from ROK, Thailand and Myanmar were used to determine 
sequence diversity of pvmsp1p along with PlasmoDB database in this study. P. vivax genomic DNA was extracted 
from whole blood samples of vivax malaria patients using the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s protocol. The pvmsp1p-19 gene was amplified by the forward primer 
(5′-GACACCCTACACACAATCAACACT-3′) and reverse primer (5′- CTACGCAGTGACGAACGCGAGG-3′) 
with AccuPower® Pfu PCR premix (Bioneer, Seoul, ROK) polymerase. The amplicon nucleotide sequence was 
analysed by the internal primer (5′-TGAAGTGCAACACGTGGAAT-3′) using an ABI 3700 Genetic Analyzer 
(Genotech, Daejeon, ROK). All the raw sequences were analysed and trimmed using the SeqMan software, 
Lasergene ver. 7.0 (DNASTAR, Madison, WI, USA).
Sequence diversity (π) and graphical visualization of thirty isolates from newly sequenced in this study and 
sixty-six pvmsp1p worldwide sequence from PlasmoDB were analysed using the sliding window option with 
window length 100 and step size 25 sites in DNAsp ver. 5.0 software.
Accession numbers. The nucleotide sequences of PvMSP1P-19 sequences are available under GenBank 
Accession Numbers MF968906 to MF968935.
Monoclonal antibody production. Recombinant PvMSP1P-19 (rPvMSP1P-19) was expressed by the 
wheat germ cell-free system (WGCF) (Cell-free Science, Matsuyama, Japan) and recombinant protein was 
confirmed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described previ-
ously19. Briefly, pEU-E01-His-TEV-MCS (Cell-free Science) vector were cloned with PvMSP1P-19 fragment. The 
recombinant protein expression was scaled up as large scale WGCF expression system manufacture’s protocol 
and purified with Ni-affinity chromatography. For monoclonal antibody production, female BALB/c mice were 
immunized intravenously with an rPvMSP1P-19 mixture containing Freund’s complete adjuvant (Sigma-Aldrich, 
St. Louis, MO, USA) and boosted at a two-week interval with an rPvMSP1P-19 mixture containing Freund’s 
incomplete adjuvant (Sigma-Aldrich). Four days later, anti-PvMSP1P-19 polyclonal antibodies were collected, 
and the spleen was used to produce hybridoma cell lines, as done previously49,50. Hybridoma culture supernatants 
Peptide
No. of patient samples
95% CIb MFIc
No. of healthy samples
95% CI MFI p valuee Fold increase+ve − ve Total (%)a +ve − ve Total (%)d
A1746 3 27 30 (10.0) 3.5–25.6 38744.2 2 28 30 (93.3) 78.7–98.2 34008.7 0.1060 1.14
C1755 2 28 30 (6.7) 1.9–21.3 24311.4 2 28 30 (93.3) 78.7–98.2 22898.6 0.4253 1.06
S1764 16 14 30 (53.3) 36.1–69.8 44943.8 1 29 30 (96.7) 83.3–99.4 27510.5 <0.0001 1.63
E1773 21 9 30 (70.0) 54.1–83.3 50022.2 1 29 30 (96.7) 83.3–99.4 27781.9 <0.0001 1.80
S1782 1 29 30 (3.3) 0.6–16.7 32749.3 0 30 30 (100.0) 88.7–100.0 30315.7 0.3558 1.08
N1791 15 15 30 (50.0) 33.2–66.9 35701.9 2 28 30 (93.3) 78.7–98.2 22036.6 <0.0001 1.62
N1800 3 27 30 (10.0) 3.5–25.6 30041.4 1 29 30 (96.7) 83.3–99.4 26401.4 0.0654 1.14
C1809 6 24 30 (20.0) 9.5–37.3 33644.1 0 30 30 (100.0) 88.7–100.0 28395.4 0.0272 1.19
C1818 8 22 30 (26.7) 14.2–44.5 15419.2 1 29 30 (96.7) 83.3–99.4 10728.0 0.0012 1.44
Table 2. Sensitivity and specificity of PvMSP1P-19 B-cell epitopes in P. vivax patients and healthy individuals. 
aSensitivity: percentage of positive patient samples. bCI: confidence interval. cMFI: mean fluorescence intensity. 
dSpecificity: percentage of negative healthy samples. eDifferences in the total IgG prevalence for each antigen 
between vivax patients and healthy individuals were calculated using Student’s t-test. A p value < 0.05 is 
considered statistically significant.
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were screened for antibody reactivity by enzyme-linked immunosorbent assay (ELISA) and indirect immunoflu-
orescence assay (IFA). Positive cells were cloned by two rounds of limiting dilution, and the antibody isotype was 
determined using a monoclonal antibody isotyping kit (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) 
according to the manufacturer’s protocol. The cloned cell lines were expanded as ascites in mice primed with pris-
tane (Wako Pure Chemical Industries, Osaka, Japan). Immunoglobulin G (IgG) was purified from the ascitic fluid 
using the MAbTrap Kit by following the manufacturer’s protocol (GE Healthcare, Little Chalfont, UK).
Erythrocyte binding inhibition assay. The PvMSP1P-19 construct and associated primers were described 
previously19. Briefly, the PvMSP1P-19-containing pEGFP-HSVgD vector was used for target expression on the 
COS-7 cell surface. The PvMSP1P-19 amplicon was ligated using the In-Fusion® HD Cloning Kit (Clontech, Palo 
Alto, CA, USA). This construct was cloned in JM109 competent cells (Real Biotech Corporation, Taiwan), and 
plasmid DNA was purified by the Ultrapure plasmid extraction system (Viogene, Taipei, Taiwan) according to 
the manufacturer’s protocol.
COS-7 cells were cultured in 24-well culture plates (Corning Inc., NY, USA) and transfected with 100 ng 
of PvMSP1P-19 construct in each well by Lipofectamine® 2000 (Invitrogen, Carlsbad, CA, USA). At 42 hours 
post-transfection, COS-7 cells were pre-incubated with 10 ug/ml to 0.625 ug/ml dilutions of monoclonal anti-
bodies for 1 hour at 37 °C. The monoclonal antibodies were washed out with PBS, and COS-7 cells were incubated 
with 10% haematocrit (Htc.) of erythrocytes in incomplete DMEM for 2 hours at 37 °C. Unbound erythrocytes 
were washed five times with PBS, and the number of rosettes in 30 fields was counted under microscopy using a 
200x objectives lens. The erythrocyte binding inhibition abilities of the monoclonal antibody was compared with 
the un-treated control. A positive rosette was counted when adherent erythrocytes covered more than 50% of the 
COS-7 cell surface. The protein expression level was determined by detecting green fluorescence protein (GFP) in 
unfixed cells on a Fluoview® FV1000 Laser Scanning Confocal Imaging System (Olympus, Tokyo, Japan) under 
the 20x objective lens.
Peptide synthesis. The P. vivax Salvador-I strain sequence was used for synthesis of PvMSP1P-19 pep-
tides. Sequential 18-mer peptides on 9-mer overlapping amino acids were chemically synthesized using Multiple 
Peptide Synthesis techniques in Solid Phase. The identity and purity of the peptides were analysed by analytical 
reversed phase-high-performance liquid chromatography (RP-HPLC) and mass spectrometry MALDI-TOF. All 
peptides solubilized in DMSO with more than 90% purity. The peptide sequence and information are described 
in Fig. 1a.
Mapping the linear epitope for monoclonal antibodies and clinical isolates. Three-aminopropyl- 
coated glass slides were prepared as described previously4. Each peptide was labelled with Cy5 NHS-Ester (GE 
Healthcare) for array slide printing efficiency calculation. The peptides were diluted with 100 mM sodium bicar-
bonate buffer (pH 8.3) and 2 µg of Cy5 NHS-Ester (GE Healthcare) and incubated on ice for 2 hours. The reac-
tion mixture was quenched with 1 M Tris-HCl (pH 8.0) solution and purified by Sephadex G-25 columns (GE 
Healthcare). The labelled peptides were diluted with 400 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC; Thermo Fisher Scientific Inc., Rochester, NY, USA) and 100 mM N-hydroxysuccinimide (NHS; Thermo 
Fisher Scientific Inc.) for peptide coupling to the amine slide. A total of 100 ng/μl of each peptide mixture was 
printed on the amine slide spot and incubated for 30 minutes at room temperature. The peptide printing effi-
ciency was calculated by the Odyssey infrared imaging system (LI-COR Bioscience). The peptide printed array 
slides were probed with 1:200 dilution monoclonal antibodies for determining the monoclonal antibody binding 
epitope or probed with a 1:25 dilution of patient sera to identify the PvMSP1P-19 B-cell epitope in vivax patient. 
The arrays for visualization were incubated with 50 ng/μl goat anti-mouse and -human Alexa Fluor 546 antibodies 
(Invitrogen) and scanned in an Innoscan-300 (Innopsys, Carbonne, France).
P. knowlesi in vitro culture and invasion inhibition assay. The human erythrocyte-adapted P. know-
lesi A1-H.1 strain (PkA1-H.1, a kind gift from Robert W. Moon, LSHTM)51 was cultured with erythrocytes 
from O+ type blood samples. The parasite was cultured in RPMI-1640 medium containing sodium bicarbonate, 
dextrose anhydrous, hypoxanthine, Albumax II (0.05%), pooled human AB sera (10%) and Gentamicin. The 
schizont stage parasite was synchronized by magnetic-activated cell sorting (MACS) (Miltenyi Biotec, Bergisch 
Gladbach, Germany) with an LD column (Miltenyi Biotec) and sub-cultured for 10 hours with fresh medium, 
erythrocytes and 100 μg/ml PvMSP1P-19 monoclonal antibodies. The sub-cultured parasites were adjusted to 
1.5% parasitaemia with 2% haematocrit. Additionally, 25 μg/mL DARC monoclonal antibody (2C3) (a kind gift 
from Renia L, Singapore Immunology Network-BMSI-A STAR) was used as an invasion blocking control25,26. 
After invasion, the ring stage was examined by thin smear with Giemsa staining under light microscopy and 
fluorescence-activated cell sorting (FACS). For FACS analysis, newly infected RBCs were fixed with glutaralde-
hyde (0.05%) and stained with SYBR green (Invitrogen). The data were analysed by a FACS Accuri™ C6 Flow 
Cytometer (Becton-Dickinson Co., Mansfield, MA, USA) with 200,000 total cell events.
Immunoblot analysis. The PvMSP1P-19 recombinant protein (rPvMSP1P-19) with His-tag19, rPkM-
SP1P-19 with GST-tag (unpublished data) and P. knowlesi schizont lysate were separated by 13% SDS-PAGE 
and transferred to a PVDF membrane (Millipore, Bedford, MA, USA) by electrophoresis. The primary antibody 
was used at 1:1,000 dilution of anti-Penta-His mouse antibody (QIAGEN, Hilden, Germany) for rPvMSP1P-19, 
1:10,000 dilution of anti-GST mouse monoclonal antibody (Novagen, Madison, WI, USA) for rPkMSP1P-10 
in PBS-T for 1 hour at 25 °C. After primary antibody reactions, the membrane was incubated with a 1:10,000 
dilution of goat anti-mouse IRDye®800 Secondary Antibody (LI-COR Bioscience, Lincoln, NE, USA) in PBS-T 
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for 1 hour at 25 °C. Data were measured using the Odyssey infrared imaging system (LI-COR Bioscience) and 
analysed with Odyssey software (LI-COR Bioscience).
Immunofluorescence assay. P. vivax thin smears from Korean isolates schizonts and P. knowlesi A1-H.1 
schizonts were prepared with ice cold acetone fixation, and the smears were blocked with 5% BSA in PBS for 
30 minutes at 37 °C. The parasite smears were incubated with a 1:100 dilution of mice monoclonal antibodies and 
anti-PvMSP1-19 antibody from rabbit for 1 hour at 37 °C, followed by incubation with a 1:500 dilution of Alexa 
Fluor 488 conjugated goat anti-mouse IgG (Invitrogen) and Alexa Fluor 546 conjugated goat anti-rabbit IgG 
(Invitrogen) as secondary antibodies for 30 minutes at 37 °C. The parasite nuclei were stained with 2 μg/ml DAPI 
(4′,6-diamidino-2-phenylindole) in the secondary antibody mixture. Slides were mounted by ProLong® Gold 
Antifade reagent (Invitrogen) and visualized by a Fluoview® FV1000 Laser Scanning Confocal Imaging System 
(Olympus, Tokyo, Japan) under the 60x objective oil-immersion lens. Images were visualized by FV10-ASW 3.0 
viewer software.
Statistical analysis. The binding inhibition assay and peptide array data were analysed using GraphPad 
Prism (GraphPad Software, San Diego, CA, USA) and Microsoft Excel 2013 (Microsoft, Redmond, WA, USA). 
Student’s t-test was used to compare the experimentally measured values for each group of the erythrocyte bind-
ing inhibition on monoclonal antibodies and peptide array for the linear B-cell epitope in patients. The signifi-
cance of the P. knowlesi invasion inhibition assay results was determined with one-way ANOVA with the Tukey 
post-test, and p < 0.05 was considered significant.
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